The Value of Progesterone for the Timing of the Embryo Transfer in IVF/ICSI: a Prospective Randomised Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03162315

Enrollment

Registered

2017-05-22

Start date

2016-03-31

Completion date

2018-08-03

Last updated

2020-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Pregnancy Rate

Brief summary

At the start of the controlled ovarian stimulation as a part of the IVF/ICSI treatment patients are informed about this trial. In case they gave informed consent and they have a progesterone level between 1 and 1.5 ng/ml at the day of the hCG injection, they will be randomised. One group of patients will have a fresh embryo transfer, in the second group all embryos will be cryopreserved and transfered in a subsequent (natural or artificial) cycle. The aim of this study is to compare clinical pregnancy rate between the two groups.

Interventions

PROCEDUREFreeze all

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* IVF/ICSI treatment * progesterone \> 1 ng/ml and ≤ 1.5 ng/ml

Exclusion criteria

* \> 40 years * AMH ≤ 1 ng/ml * Conditions influencing pregnancy rate (e.g. hydrosalphinx, uterus malformation, hyperprolactinemia and other endocrine conditions; with the exception of controlled thyroid function disease) * no available progesterone value on the day of hCG-injection

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate	7 gestational weeks

Secondary

Measure	Time frame
Ongoing pregnancy rate	25 gestational weeks
Live birth rate	Delivery

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026